Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Classen HG  
Magnesium-L-Aspartate Hydrochloride: Experimental and Clinical Data

Journal of Clinical and Basic Cardiology 2002; 5 (1): 43-47

PDF    Summary    Figures   

Fig. 1: Magnesium-L-Aspartat - Strukturformel Fig. 2: Kalzium - Magnesium - Antagonismus Fig. 3: Magnesium-L-Aspartat - Magnesium

Keywords: KalziumantagonismusKinetikStressprotektionStudieSäuren-Basen-Metabolismusacid-base metabolismCa antagonismclinical studiescompatibilitykineticsstress protection

Epidemiological data suggest that plentiful magnesium (Mg) supply decreases the risk of cardiovascular and other stress-related diseases. Magnesium-L-aspartate hydrochloride (MAH) contains equimolar amounts of Mg and chloride and hence does not affect the equilibrium of non-metabolizable acids and bases. MAH is safe, main pharmacological actions are mediated via Mg-ions and their Ca2+-antagonistic activity. MAH does not bind gastric hydrochloric acid and does not interfere with the enteral absorption of iron, potassium and calcium under physiological conditions, nor with the cytostatic activity of cisplatin and cyclosporine. "Low utilizers" of oral supplements need higher than standard doses (15 mmol) of MAH, individual doses must be increased up to 30-40 mmol. MAH has been proven to attenuate stress reactions in experimental animals, livestock and in humans. Beneficial effects are proven under numerous clinical conditions, eg in obstetrics and gynaecology, in pediatry, cardiology, internal medicine and traumatology. Oral therapy can be optimized by observing plasma/serum and urine Mg levels.
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum